Business
Tenaya Highlights Growing Capabilities in AAV Manufacturing, Capsid Engineering and Expansion into Gene Editing with Six Abstracts Accepted for Presentation at the ASGCT 26th Annual Meeting
Continued Innovation Across Platforms Facilitates Current Pipeline Advancements and Increases Opportunities for Future Pipeline Candidates SOUTH SAN
About this update from Tenaya Therapeutics, Inc.
[{"type":"text","content":"Continued Innovation Across Platforms Facilitates Current Pipeline Advancements and Increases Opportunities for Future Pipeline Candidates\nSOUTH SAN FRANCISCO, Calif., May 03, 2023 (GLOBE NEWSWIRE) -- Tenaya Therapeutics, Inc. (NASDAQ: TNYA), a clinical-stage biotechnology company with a mission to discover, develop and deliver potentially curative therapies that address the underlying causes of heart disease, announced that several abstracts have been accepted for presentation at the American Society of Gene and Cell Therapy (ASGCT) 26th Annual Meeting detailing the company’s expanded capabilities for manufacturing and discovering genetic medicines for heart disease. “Tenaya was founded with a singular focus on developing novel medicines for rare and prevalent forms of heart disease. To be a leader in this space requires a sustained commitment to differentiated platform capabilities that enable us to optimize the product profile for our therapeutic candidates and to address new conditions where there is high unmet need,” said Faraz Ali, Chief Executive Officer of Tenaya. “The presentations at this year’s ASGCT highlight innovations in manufacturing, capsid engineering and gene editing, that support the advancement of our current pipeline and create new opportunities for future pipeline candidates. We look forward to sharing work on additional innovative enabling technologies and genetic medicine programs at future meetings.” The ASGCT 26th Annual Meeting is being held in Los Angeles, California May 16-20, 2023. Details of the company’s upcoming presentations at ASGCT are available below: Manufacturing and Process DevelopmentTN-201 is an adeno-associated virus (AAV) gene therapy being advanced into the clinic for the treatment of MYBPC3-associated hypertrophic cardiomyopathy (HCM). Clinical supply of TN-201 was manufactured under current Good Manufacturing Practice regulations at Tenaya’s Genetic Medicines Manufacturing Center using the company’s proprietary Sf9 recombinant baculovirus (Sf9/rBV) production process at the 1000L scale. At ASGCT, Tenaya researchers will present data detailing the scale up, formulation and purification techniques deployed in the successful initial manufacture of TN-201. In addition to the Sf9/rBV manufacturing platform, Tenaya has also internalized the HEK293 manufacturing platform up to the 200L s...